Sirius Therapeutics launches SRSD107 Phase 1 trial, targeting thromboembolic disorders

Sirius Therapeutics, a pioneering biotechnology firm, has marked a significant milestone in the development of novel treatments for cardiovascular diseases by dosing the first subject ... Read More